Immunotherapy
Point-of-care manufacturing delivers effective CAR T cells faster
On-site manufacturing of autologous adoptive cell therapy products resulted in similarly effective treatments in far less time compared with commercially manufactured therapies, according to results of a comparison analysis published in Journal for ImmunoTherapy of Cancer.
EULAR: Rheumatologist, oncologist collaboration 'pivotal' to enhance checkpoint inhibitor management
Oncologists should be encouraged to promptly consult with rheumatologists in the event of suspected immune-related adverse events due to checkpoint inhibitor therapy, according to a series of “points to consider” published by EULAR in the Annals of the Rheumatic Diseases.
Lung cancer management in the COVID-19 era requires an individualized approach
Amid the COVID-19 pandemic, it is important to pay close attention to individual clinical and radiological pulmonary signs of patients with lung cancer while awaiting specific evidence-based treatment guidelines.
Parker Institute for Cancer Immunotherapy awards grants to six early career researchers
Viaskin Peanut patch increases protection from allergy over time
In the largest long-term peanut immunotherapy trial to date, the epicutaneous immunotherapy patch known as Viaskin Peanut increased patients’ protection over time from allergic reactions, according to researchers.
Researchers develop AI-based projects for tumor scoring, vessel annotation
Reidunn Edelmann, PhD, has always been interested in blood vessels.
Q&A: The role of PCPs in cancer care
The American Cancer Society estimates there will be approximately 1.8 million new cancer diagnoses and 606,520 cancer-related deaths in the United States this year. As of January 2019, there were about 16.9 million cancer survivors in the country, representing approximately 5% of the U.S. population, according to the National Cancer Institute.
12 medical centers form brain tumor research collaborative
Durvalumab plus chemotherapy, without tremelimumab, extends OS in small cell lung cancer
The addition of durvalumab to a choice of standard-of-care first-line chemotherapies conferred a sustained OS benefit for patients with extensive-stage small cell lung cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.
Despite advances, rheumatic effects of checkpoint therapy poorly defined
SCOTTSDALE, Arizona — The rheumatic effects of checkpoint therapy remain, despite their increased spotlight in recent years, among the most poorly defined of the immune-related adverse events associated with the emerging cancer treatment, according to Cassandra Calabrese, DO, of the Cleveland Clinic.